Loading…
Ginkgo Bioworks Holdings, Inc. is projected to rise to $9.32 by 2027, a +15% move from its current price of $8.09. DNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $7.80 | $8.09 | $8.39 | -0.03% |
| Aug 3 | $7.68 | $8.08 | $8.51 | -0.07% |
| Aug 4 | $7.59 | $8.08 | $8.61 | -0.10% |
| Aug 5 | $7.51 | $8.08 | $8.69 | -0.14% |
| Aug 6 | $7.44 | $8.08 | $8.76 | -0.17% |
| Aug 7 | $7.38 | $8.07 | $8.83 | -0.21% |
| Aug 8 | $7.33 | $8.07 | $8.89 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.33 | $8.07 | $8.89 | -0.24% |
| Week 2 | $7.02 | $8.05 | $9.23 | -0.49% |
| Week 3 | $6.79 | $8.03 | $9.50 | -0.73% |
| Week 4 | $6.60 | $8.01 | $9.72 | -0.97% |
| Week 5 | $6.44 | $7.99 | $9.92 | -1.21% |
| Week 6 | $6.29 | $7.97 | $10.11 | -1.45% |
| Week 7 | $6.16 | $7.95 | $10.27 | -1.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ginkgo Bioworks Holdings, Inc. is a biotechnology company that develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments, offering cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.
It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats.
In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc.
was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company with a current price of $8.09 and a market cap of $528.48M. It is ranked 2809 in market capitalization.
The price outlook from the forecast shows a path of moderate gains with some volatility. The 2026 forecast lists an average price of $8.09, a low of $5.48, and a high of $10.75, with an ROI of 0 and sentiment NEUTRAL.
From 2027 onward, the forecast projects higher averages: 2027 avg $9.37, 2028 avg $9.24, 2029 avg $10.03, 2030 avg $12.59, 2031 avg $15.49, 2032 avg $18.06, 2033 avg $17.67, 2034 avg $17.61, 2035 avg $20.57; the outlook remains BULLISH for the later years, with ROIs of 55.6 (2030), 91.5 (2031), 123.2 (2032), 118.5 (2033), 117.7 (2034), and 154.3 (2035). The forecast continues with 2040 avg $31.16 and ROI 285.1, and 2050 avg $71.03 with ROI 778, both labeled BULLISH.
A major floor 32.3% below — a decisive break under it would weaken the trend.
The nearest floor, 9.0% below — buyers have tended to step in here.
The nearest ceiling, 28.6% above — a clean break opens room to run.
A major ceiling 44.1% above — clearing it would confirm fresh momentum.
Key DNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.79 | Buy | $7.90 | Buy |
| MA 10 | $7.75 | Buy | $7.96 | Buy |
| MA 20 | $8.41 | Sell | $8.25 | Sell |
| MA 50 | $8.71 | Sell | $8.49 | Sell |
| MA 100 | $8.13 | Sell | $8.54 | Sell |
| MA 200 | $8.85 | Sell | $9.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.08 | Neutral |
| Stoch RSI (14) | 85.36 | Sell |
| CCI (20) | -29.46 | Neutral |
| Williams %R (14) | -56.55 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -10.11 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 43.45 | Neutral |
| TRIX (15) | -0.50 | Sell |
| Awesome (5,34) | -0.99 | Sell |
| Ultimate (7,14,28) | 50.03 | Neutral |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 7.94 | Buy |
| ADX (14) | 17.03 | Neutral |
| ATR (14) | 0.28 | Info |
The 30-day technical picture shows Neutral sentiment, RSI14 at 50, and moving averages around the price. The SMA50 is $8.70 and the SMA200 is $8.87, with a near-term support at $7.36 and resistance at $10.40. The 30-day range spans from $6.31 to $10.37, reflecting a mix of upside potential and downside risk over the near term.
Volatility remains substantial, as indicated by an annualized volatility of 70%, consistent with a wide trading range in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.48 | $8.09 | $10.70 | 0% | Neutral | |
| $7.21 | $9.32 | $12.88 | +15% | Neutral | |
| $6.81 | $9.16 | $13.28 | +13% | Neutral | |
| $7.13 | $9.92 | $14.92 | +23% | Bullish | |
| $8.59 | $12.29 | $19.08 | +52% | Bullish | |
| $10.22 | $15.03 | $23.95 | +86% | Bullish | |
| $11.63 | $17.53 | $28.61 | +117% | Bullish | |
| $11.13 | $17.18 | $28.65 | +112% | Bullish | |
| $10.81 | $17.07 | $29.04 | +111% | Bullish | |
| $12.32 | $19.88 | $34.43 | +146% | Bullish | |
| $16.71 | $29.84 | $55.73 | +269% | Bullish | |
| $31.31 | $67.05 | $139.57 | +729% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.48 | $8.09 | $10.02 | +0.00% |
| September 2026 | $6.81 | $8.14 | $10.06 | +0.59% |
| October 2026 | $6.50 | $7.84 | $9.82 | -3.70% |
| November 2026 | $6.59 | $8.01 | $10.15 | +2.20% |
| December 2026 | $6.83 | $8.35 | $10.70 | +4.31% |
Click any year to see its month-by-month DNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ginkgo Bioworks Holdings, Inc.'s 2026 outlook centres on $8.09, within a $5.48 to $10.70 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, DNA could reach as high as $12.88, with a base case around $9.32 and support toward $7.21 — roughly +15% from $8.09. A consolidation phase looks the most probable path here.
Expect DNA to range from $6.81 to $13.28 through 2028. The $9.16 average target implies a +13% move from current prices. That is -2% versus the projected 2027 average. Price action looks broadly range-bound.
The DNA price prediction for 2029 points to an average of $9.92 (low $7.13, high $14.92) — a potential gain of +23% on today's $8.09. Buyers look set to stay in control over this stretch.
In 2030, DNA is projected to trade between $8.59 and $19.08, averaging $12.29 — a potential gain of +52% from today's $8.09. That is up +24% on the projected 2029 average. Momentum favours further upside here.
Ginkgo Bioworks Holdings, Inc.'s 2031 outlook centres on $15.03, within a $10.22 to $23.95 range. That is up +22% on the projected 2030 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, DNA could reach as high as $28.61, with a base case around $17.53 and support toward $11.63 — roughly +117% from $8.09. Momentum favours further upside here.
Expect DNA to range from $11.13 to $28.65 through 2033. The $17.18 average target implies a +112% move from current prices. That is -2% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The DNA price prediction for 2034 points to an average of $17.07 (low $10.81, high $29.04) — a potential gain of +111% on today's $8.09. Momentum favours further upside here.
In 2035, DNA is projected to trade between $12.32 and $34.43, averaging $19.88 — a potential gain of +146% from today's $8.09. That is up +16% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Ginkgo Bioworks Holdings, Inc.'s 2040 outlook centres on $29.84, within a $16.71 to $55.73 range. That is up +50% on the projected 2035 average. That marks a +269% change versus current levels. Momentum favours further upside here.
By 2050, DNA could reach as high as $139.57, with a base case around $67.05 and support toward $31.31 — roughly +729% from $8.09. Buyers look set to stay in control over this stretch.
Investing $1,000 in DNA today (≈ 123.609394 DNA) could be worth
$8,288.49
+$7,288.49 (+729%) by 2050 · US Dollar
Based on the average projected DNA price of $67.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNAwould be worth at today's price.
$1,000 invested in DNA on Jul 31, 2025 (≈ 76.103499 DNA) would be worth
$615.68
-$384.32 (-38.4%) today · 0.62× · US Dollar
Based on a DNA entry price of $13.14 vs. today's $8.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.36 | $1,099.18 | +9.9% |
| 1 month ago | $10.28 | $786.97 | -21.3% |
| 3 months ago | $9.7 | $834.02 | -16.6% |
| 6 months ago | $9.16 | $883.19 | -11.7% |
| 1 year ago | $13.14 | $615.68 | -38.4% |
| All time (5.0y) ago | $394.8 | $20.49 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNA forecast.
Our base-case forecast reaches $16.00 around 2032.
Implied market cap at $16.00: $853.78M
The multi-year forecast highlights a bullish trajectory beginning in the late 2020s and continuing into the 2030s and beyond. In 2030 the average forecast is $12.59 with an ROI of 55.6, followed by continued upside through 2031 ($15.49, ROI 91.5) and 2032 ($18.06, ROI 123.2). The 2033–2035 period shows elevated levels, with 2033 at $17.67 (ROI 118.5), 2034 at $17.61 (ROI 117.7), and 2035 at $20.57 (ROI 154.3).
The horizon then extends to 2040 with an average of $31.16 (ROI 285.1) and to 2050 with an average of $71.03 (ROI 778), all under a BULLISH sentiment. These figures imply meaningful long-run upside, but they carry inherent uncertainty and are not guarantees.
Across 2026–2050, the outlook shifts from a Neutral stance in the near term to sustained bullishness in the longer term, suggesting higher price potential if the forecast assumptions hold. Investors should weigh the favorable longer-run projections against the possibility of near-term volatility and market-driven fluctuations.
Tap a question to reveal the answer.
2030 forecast: average price $12.59, with a min of $8.72 and max of $19.69; ROI 55.6; sentiment BULLISH.
Forecasts show a bullish sentiment from 2029 onward with rising averages and ROIs, including 2030 (ROI 55.6) and 2040 (ROI 285.1). These are estimates, not guarantees, and come with uncertainty.
The 2030 forecast max is $19.69, which is just below $20.
Current price is $8.09 and market cap is $528.48M.
2040 average price is $31.16 with ROI 285.1; 2050 average price is $71.03 with ROI 778; both scenarios are labeled BULLISH.
Ginkgo Bioworks Holdings, Inc. Community Discussion
0Share your Ginkgo Bioworks Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.